Ocuphire Pharma (OCUP)
(Delayed Data from NSDQ)
$1.67 USD
-0.07 (-4.02%)
Updated Apr 18, 2024 04:00 PM ET
After-Market: $1.67 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth B Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
OCUP 1.67 -0.07(-4.02%)
Will OCUP be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for OCUP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OCUP
Ocuphire (OCUP) to Report Q4 Earnings: What's in the Cards?
Here's Why You Should Invest in Ocuphire Pharma (OCUP) Now
OCUP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Merck (MRK) Gets EU Nod for Expanded Use in Gastric Cancer
FDA Expands Merck's (MRK) Welireg Label in Renal Cell Carcinoma
Moderna (MRNA) Soars on Upbeat Data From Cancer Therapy Study
Other News for OCUP
Ocuphire Pharma Incentivizes Director Pepose with Stocks and Options
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
Ocuphire Pharma announces enrollment of first patient in LYNX-2 Phase 3 study
12 Health Care Stocks Moving In Thursday's After-Market Session
Analysts Offer Insights on Healthcare Companies: Smith & Nephew Snats (SNN), Ocuphire Pharma (OCUP) and Vertex Pharmaceuticals (VRTX)